# Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

> **NCT00699491** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 48 (actual)

## Conditions studied

- Male Breast Carcinoma
- Recurrent Breast Carcinoma
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

- **BIOLOGICAL:** Cixutumumab
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT00699491
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-31
- **Primary completion:** 2013-09-09
- **Final completion:** 2018-02-14
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00699491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00699491, "Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00699491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*